Strides Arcolab is currently trading at Rs. 933.40, up by 5.90 points or 0.64% from its previous closing of Rs. 927.50 on the BSE.
The scrip opened at Rs. 933.95 and has touched a high and low of Rs. 937.30 and Rs. 928.60 respectively. So far 13535 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 999.00 on 05-Dec-2014 and a 52 week low of Rs. 343.80 on 26-Feb-2014.
Last one week high and low of the scrip stood at Rs. 960.45 and Rs. 914.50 respectively. The current market cap of the company is Rs. 5563.43 crore.
The promoters holding in the company stood at 27.67% while Institutions and Non-Institutions held 46.79% and 25.54% respectively.
Strides Arcolab’s wholly owned subsidiary - Strides Pharma Global, Singapore (Strides Pharma Global) has been awarded ‘International Headquarters Status’ by the Singapore Economic Development Board (EDB). Strides Pharma Global proposes to carry out activities for its international business including business development and planning, sales and marketing, intellectual property management, global supply chain management and global regulatory affairs.
Strides Pharma Global will also be building a new manufacturing facility in Singapore in the next couple of years with focus on the regulated and South East Asia markets.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: